Literature DB >> 15519663

Angiogenesis and hepatocellular carcinoma.

David Semela1, Jean-François Dufour.   

Abstract

Entities:  

Mesh：

Year:  2004        PMID： 15519663     DOI： 10.1016/j.jhep.2004.09.006

Source DB:  PubMed          Journal:  J Hepatol        ISSN： 0168-8278            Impact factor:   25.083


× No keyword cloud information.
  127 in total

1.  The diffusion-weighted imaging perfusion fraction f is a potential marker of sorafenib treatment in advanced hepatocellular carcinoma: a pilot study.

Authors:  Maïté Lewin; Laetitia Fartoux; Alexandre Vignaud; Lionel Arrivé; Yves Menu; Olivier Rosmorduc
Journal:  Eur Radiol       Date:  2010-08-05       Impact factor: 5.315

2.  Delivery of siRNA Using CXCR4-targeted Nanoparticles Modulates Tumor Microenvironment and Achieves a Potent Antitumor Response in Liver Cancer.

Authors:  Jia-Yu Liu; Tsaiyu Chiang; Chun-Hung Liu; Guann-Gen Chern; Ts-Ting Lin; Dong-Yu Gao; Yunching Chen
Journal:  Mol Ther       Date:  2015-08-17       Impact factor: 11.454

Review 3.  Current status and perspective of antiangiogenic therapy for cancer: hepatocellular carcinoma.

Authors:  Shinji Tanaka; Shigeki Arii
Journal:  Int J Clin Oncol       Date:  2006-04       Impact factor: 3.402

4.  Recombinant vascular basement-membrane-derived multifunctional peptide inhibits angiogenesis and growth of hepatocellular carcinoma.

Authors:  You-Hua Wu; Jian-Guo Cao; Hong-Lin Xiang; Hong Xia; Yong Qin; A-Ji Huang; Di Xiao; Fang Xu
Journal:  World J Gastroenterol       Date:  2009-04-14       Impact factor: 5.742

5.  Treating hepatocellular carcinoma progression following first-line sorafenib: therapeutic options and clinical observations.

Authors:  A Ruth He; Alec S Goldenberg
Journal:  Therap Adv Gastroenterol       Date:  2013-11       Impact factor: 4.409

6.  Dual Programmed Death Receptor-1 and Vascular Endothelial Growth Factor Receptor-2 Blockade Promotes Vascular Normalization and Enhances Antitumor Immune Responses in Hepatocellular Carcinoma.

Authors:  Kohei Shigeta; Meenal Datta; Tai Hato; Shuji Kitahara; Ivy X Chen; Aya Matsui; Hiroto Kikuchi; Emilie Mamessier; Shuichi Aoki; Rakesh R Ramjiawan; Hiroki Ochiai; Nabeel Bardeesy; Peigen Huang; Mark Cobbold; Andrew X Zhu; Rakesh K Jain; Dan G Duda
Journal:  Hepatology       Date:  2019-10-14       Impact factor: 17.425

Review 7.  Diagnosis of hepatocellular carcinoma.

Authors:  Asmaa I Gomaa; Shahid A Khan; Edward L S Leen; Imam Waked; Simon D Taylor-Robinson
Journal:  World J Gastroenterol       Date:  2009-03-21       Impact factor: 5.742

8.  Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma.

Authors:  Abby B Siegel; Emil I Cohen; Allyson Ocean; Deborah Lehrer; Alec Goldenberg; Jennifer J Knox; Helen Chen; Sean Clark-Garvey; Alan Weinberg; John Mandeli; Paul Christos; Madhu Mazumdar; Elizabeta Popa; Robert S Brown; Shahin Rafii; Jonathan D Schwartz
Journal:  J Clin Oncol       Date:  2008-06-20       Impact factor: 44.544

9.  Hepatocellular carcinomas in cirrhotic and noncirrhotic human livers share angiogenic characteristics.

Authors:  Wenjiao Zeng; Annette S H Gouw; Marius C van den Heuvel; Grietje Molema; Sibrand Poppema; Eric J van der Jagt; Koert P de Jong
Journal:  Ann Surg Oncol       Date:  2010-01-20       Impact factor: 5.344

10.  Hypoxia, angiogenesis and liver fibrogenesis in the progression of chronic liver diseases.

Authors:  Claudia Paternostro; Ezio David; Erica Novo; Maurizio Parola
Journal:  World J Gastroenterol       Date:  2010-01-21       Impact factor: 5.742
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.